Clinical trial NCT03535766: An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions
Official title: An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Lead sponsor: St Elizabeth Healthcare
Sponsor class: OTHER
First posted: 2018-05-24
Enrollment: 2100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion.

Brief summary: This study is a single center, minimal risk, physician initiated retrospective chart review. An analysis of treatment timelines for patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion. The study investigator and designee(s) will review patient electronic medical records, extracting data related to the symptom presentation, diagnosis, and treatment of new diagnoses of lung cancer. Collected data will focus on dates of encounters, diagnostic imaging/procedures, and treatments, with data analysis evaluating time between care encounters and potential delays in care. The data will be further stratified based on system-wide changes implemented to improve efficiency, patient outcomes, and patient experience.


Eligibility criteria: Inclusion Criteria:

* Patient seen within the St. Elizabeth system
* \>=18 years of age
* New diagnosis of histologically or cytologically documented primary lung cancer diagnosed January 2013 or later

Exclusion Criteria:

* Patients with metastatic lung disease of other primary
* Other malignancies at investigator's discretion
* Patient received treatment at a facility outside of St. Elizabeth where records are not available through EPIC
* Patient currently undergoing treatment for new diagnosis of lung cancer

Primary outcomes:
measure: Time from presentation to treatment
timeFrame: from initial patient presentation with symptoms or incidental finding to first day of treatment, up to 3 years
Secondary outcomes:
measure: Additional time between imaging and physician referrals
timeFrame: From identification of concerning nodule to specialist appointment, up to 3 years
Other outcomes:
Locations:
city: Edgewood
country: United States
facility: St. Elizabeth Healthcare
state: Kentucky
Study officials:
affiliation: St Elizabeth Healthcare
name: Royce Calhoun, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol. 2011 Jul;6(7):1254-9. doi: 10.1097/JTO.0b013e318217b623.
citation: Van de Vosse D, Chowdhury R, Boyce A, Halperin R. Wait Times Experienced by Lung Cancer Patients in the BC Southern Interior to Obtain Oncologic Care: Exploration of the Intervals from First Abnormal Imaging to Oncologic Treatment. Cureus. 2015 Sep 22;7(9):e330. doi: 10.7759/cureus.330.
citation: Vidaver RM, Shershneva MB, Hetzel SJ, Holden TR, Campbell TC. Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US-Based Study. J Oncol Pract. 2016 Jun;12(6):e643-53. doi: 10.1200/JOP.2015.009605. Epub 2016 May 3.